Navigation Links
TrinityCare Appoints Decorated Christian Artist Al Denson to Board of Directors
Date:3/20/2009

FRIENDSWOOD, Texas, March 20 /PRNewswire-FirstCall/ -- TrinityCare Senior Living, Inc. (OTC Bulletin Board: TCSR) (the "Company"), a developer, manager and owner of faith-based senior living facilities, today announced the appointment of Al Denson to the Company's Board of Directors. Mr. Denson, who will be inducted into the Christian Music Hall of Fame later in 2009, has recorded 19 number one songs, produced over 10 albums, received a Dove Award, and has performed for millions over his 30-year career in music. He also has a ministry that has been instrumental in providing respite for churches, ministries and denominations for nearly a decade.

"Al Denson has been involved in the development of TrinityCare for more than five years and has been a personal friend and business partner for nearly a quarter of a century," stated Donald W. Sapaugh, Chairman and Chief Executive Officer of TrinityCare Senior Living, Inc. "We are delighted to have Al join our board. I trust his judgment, and his counsel should prove invaluable as we embark on our expansion strategy in 2009."

About TrinityCare Senior Living

TrinityCare Senior Living ("TrinityCare") develops, owns, and manages quality senior living facilities that focus on enriching the faith of the residents and providing state-of-the-art independent living, assisted living, memory care and adult day care services in a single location. The Company partners with local churches and developers for each facility and offers a wide range of both community and personal services to residents. Headquartered in Friendswood, Texas (Houston metropolitan area) TrinityCare is a rapidly growing company with three successful facilities currently operating in Texas and Tennessee. Near-term expansion plans target the Southeastern part of the United States. For more information please visit www.trinitycare.com.

<
'/>"/>
SOURCE TrinityCare Senior Living, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. TrinityCare Senior Living, Inc. Changes Fiscal Year End to December 31st
2. TrinityCare Senior Living Trading Under New Symbol TCSR
3. WorldHeart Appoints David Pellone Chief Financial Officer
4. Novo Nordisk Appoints New Leader of North American Business
5. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
6. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
7. Resonant Medical Appoints New Vice President of Global Sales
8. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
9. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
10. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
11. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases 2Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 2Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 3Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 4Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 5Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma 6